KUALA LUMPUR: Hong Seng Consolidated Bhd's (HSC) subsidiary eMedAsia Sdn Bhd (eMedAsia) yesterday signed an exclusive partnership with CLEA Technology Sdn Bhd (CTSB), the company that provides CLEADOC virtual Covid-19 professional RTK and PCR screenings (VCS) and other related services in Malaysia.
The partnership is to provide CLEADOC VCS services to both the inbound and outbound travellers as preparation for the next phase of border reopening.
CLEADOC VCS allows foreign travellers to easily perform a professional pre-departure or on-arrival RTK test comfortably at anytime anywhere with results verified by medical doctors through in-app steps, designed by medical doctors.
The result generated from CLEADOC can be use as pre-departure result requirement or Malaysia on-arrival 24 hours requirement which are also in sync with MySejahtera status update.
Koperasi Persatuan Perubatan Malaysia (KOOP MMA) chairman and eMedAsia director Dr Thirunavukarasu Rajoo said the recent announcement to open borders is a good move to by the government to facilitate the nation's gradual yet necessary transition to an endemic phase.
"Malaysia is expected to welcome more than four million visitors while many Malaysians are expected to travel abroad following the reopening of borders.
"Therefore, we are ready to help our government and fellow travellers to fulfil the latest requirements to cross borders easily be it VCS, professional RTK-Ag tests in clinics or hotels, or on-site PCR screenings," he said in a statement.
eMedAsia is a 60 per cent-owned subsidiary under the HSC's healthcare arm HS Bio Group in partnership with Koperasi Persatuan Perubatan Malaysia (KOOP MMA), the investment arm of the Malaysia Medical Association (MMA).
eMedAsia is a joint venture company between KOOP MMA which is the investment arm for the members of the MMA.
Together with HS Bio, the aim is to digitalising the Malaysian private healthcare system and to empower potentially approximately 8,000 private clinics around Malaysia.
CLEADOC app can be download globally can be used by international travellers in bound to Malaysia.
To date CLEADOC had created more than two millions impression, screened more than 1 million tests, and has more than 200,000 active users in its platform.
Currently, CLEADOC is working closely with Singapore, Thailand and Indonesia, expanding the services to all these regions in South East Asia.
In addition, eMedAsia.com has also partnered MySafeTravel portal, the incumbent go-to government portal for travellers through a backend system integration.
Inbound travellers are able to connect with more than 2,000 registered private clinics under eMedAsia which has a geofencing feature to locate nearby clinics and even book a VCS through MySafeTravel.
This integration will be a significant convenience for travellers as they do not need to congregate at one location and potentially trigger a new cluster.
Meanwhile, outbound Malaysian travellers will be able to book both RTK-Ag and PCR tests directly via eMedAsia.com or travellers.eMedAsia.com prior to their travelling dates depending on the requirements of the specific destination country or airline.